JAK
Les inhibiteurs de la kinase Janus (JAK) sont des composés qui ciblent la voie de signalisation JAK-STAT, impliquée dans la croissance cellulaire, la réponse immunitaire et l'angiogenèse. En inhibant JAK, ces composés peuvent réduire la signalisation qui conduit à la formation de nouveaux vaisseaux sanguins dans les tumeurs, inhibant ainsi la croissance tumorale. Les inhibiteurs de JAK sont importants dans le traitement des cancers et des maladies inflammatoires. Chez CymitQuimica, nous offrons une gamme diversifiée d'inhibiteurs de JAK de haute qualité pour soutenir vos recherches en oncologie, immunologie et angiogenèse.
Produits appartenant à la catégorie "JAK"
Trier par
AMG-47a
CAS :AMG-47a inhibits Lck, T cell growth, and degrades KRAS oncoprotein, affecting EGFP-KRASG12V but not EGFP.Formule :C29H28F3N5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :535.56Ruxolitinib
CAS :Ruxolitinib (INCB018424) is a JAK1/2 inhibitor (IC50=3.3/2.8 nM) that is potent and selective.Formule :C17H18N6Degré de pureté :100% - 99.99%Couleur et forme :SolidMasse moléculaire :306.36Ref: TM-T1829
5mg58,00€10mg74,00€25mg92,00€50mg116,00€100mg155,00€200mg245,00€500mg414,00€1mL*10mM (DMSO)65,00€SHR0302
CAS :SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3,Formule :C18H22N8O2SDegré de pureté :99.11%Couleur et forme :SolidMasse moléculaire :414.48Ref: TM-T9195
1mg160,00€5mg393,00€10mg620,00€25mg1.035,00€50mg1.483,00€100mg1.882,00€1mL*10mM (DMSO)455,00€lirucitinib
CAS :Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.Formule :C16H25N5OSCouleur et forme :SolidMasse moléculaire :335.468JAK-IN-11
CAS :JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.Formule :C23H22FN5O4SDegré de pureté :99.57%Couleur et forme :SolidMasse moléculaire :483.52Tofacitinib
CAS :Tofacitinib (Tasocitinib) is an orally Janus kinase inhibitor. Tofacitinib is used for the treatment of rheumatoid arthritis. Cost effective and quality assured.Formule :C16H20N6ODegré de pureté :100% - 99.71%Couleur et forme :SolidMasse moléculaire :312.37JAK1/STAT3-IN-1
JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).Formule :C30H33FN4O3SCouleur et forme :SolidMasse moléculaire :548.67AZD-1480
CAS :AZD1480: JAK2 inhibitor, IC50 0.26 nM; selective vs Tyk2, JAK3; less on JAK1. Used in solid tumors, PPV, PMF, ET trials.Formule :C14H14ClFN8Degré de pureté :97.5% - 98.55%Couleur et forme :SolidMasse moléculaire :348.77TG101209
CAS :TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.Formule :C26H35N7O2SDegré de pureté :100% - 99.36%Couleur et forme :SolidMasse moléculaire :509.67JAK-IN-27
CAS :JAK-IN-27, also known as compound 1, is an orally active, potent inhibitor of the JAKS family kinases, displaying inhibitory concentrations (IC50s) of 3.0 nMFormule :C20H21F2N7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :413.42Curculigoside
CAS :1.Formule :C22H26O11Degré de pureté :99.85%Couleur et forme :SolidMasse moléculaire :466.44JAK2-IN-11
CAS :JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.Formule :C31H31F3N8O4Couleur et forme :SolidMasse moléculaire :639.64Fedratinib
CAS :Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.Formule :C27H36N6O3SDegré de pureté :98.23% - 99.96%Couleur et forme :SolidMasse moléculaire :524.68Ref: TM-T1995
1g625,00€5mg49,00€10mg69,00€50mg113,00€100mg134,00€200mg216,00€500mg472,00€1mL*10mM (DMSO)57,00€Pyridone 6
CAS :Pyridone 6, a selective JAK1/2/3 and Tyk2 inhibitor with IC50s: JAK1=15 nM, JAK2=1 nM, JAK3 (Ki=5 nM), Tyk2=1 nM; weakly binds other kinases (130 nM-10 μM).Formule :C18H16FN3ODegré de pureté :97.10% - 98.74%Couleur et forme :SolidMasse moléculaire :309.34Ref: TM-T3080
1mg82,00€2mg106,00€5mg162,00€10mg221,00€25mg449,00€50mg658,00€100mg939,00€500mg1.882,00€1mL*10mM (DMSO)177,00€Baricitinib
CAS :Baricitinib (INCB028050) is an orally JAK1 and JAK2 inhibitor. Baricitinib has anti-inflammatory and anti-tumor activity. Cost-effective and quality-assured.Formule :C16H17N7O2SDegré de pureté :100% - 99.79%Couleur et forme :SolidMasse moléculaire :371.42Ref: TM-T2485
5mg50,00€10mg73,00€25mg90,00€50mg115,00€100mg144,00€200mg188,00€500mg311,00€1mL*10mM (DMSO)69,00€JAK1-IN-4
CAS :JAK1-IN-4 selectively blocks JAK1 (IC50 = 85 nM) over JAK2/JAK3 and halts STAT3 phosphorylation in NCI-H 1975 cells (IC50 = 227 nM).Formule :C26H32FN9O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :521.59Filgotinib
CAS :Filgotinib (GLPG0634) is a selective JAK1 inhibitor. The IC50 values against JAK1, JAK2, JAK3, and TYK2 are 10 nM, 28 nM, 810 nM, and 116 nM, respectively.Formule :C21H23N5O3SDegré de pureté :98.03% - ≥95%Couleur et forme :SolidMasse moléculaire :425.5JAK2 Inhibitor V
CAS :JAK2 Inhibitor V (JAK2 Inhibitor V Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.Formule :C23H24N2ODegré de pureté :96.69% - 99.15%Couleur et forme :SolidMasse moléculaire :344.45Ref: TM-T3042
2mg39,00€5mg57,00€10mg85,00€25mg157,00€50mg274,00€100mg505,00€500mg1.121,00€1mL*10mM (DMSO)63,00€DPP
CAS :DPP, a Platinum(IV) complex with a pterostilbene-derived axial ligand, inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, demonstratingFormule :C36H40Cl2N2O10PtDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :926.7AJI-100
CAS :AJI-100 serves as a dual-target inhibitor, effectively blocking Aurora kinase A and JAK2, with respective IC50 values of 12.7 nM and 18.5 nM. It inhibits T cell mitosis and cell polarity by directly targeting Aurora kinase A and reduces STAT3 phosphorylation by inhibiting JAK2 activation, consequently diminishing the differentiation of TH1 and TH17 cells. This compound is utilized in researching immune response regulation and the prevention of graft-versus-host disease (GVHD).Formule :C17H14FN5OCouleur et forme :SolidMasse moléculaire :323.32TCS 21311
CAS :TCS 21311 (NIBR3049) selectively inhibits JAK3 (IC50: 8 nM) and PKCα/θ & GSK3β; >100x selective over JAK1, JAK2, TYK2.Formule :C27H25F3N4O4Degré de pureté :≥98%Couleur et forme :SolidMasse moléculaire :526.51Ruxolitinib (S enantiomer)
CAS :Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.Formule :C17H18N6Degré de pureté :99.37% - 99.79%Couleur et forme :SolidMasse moléculaire :306.36JAK2-IN-9
CAS :Compound A8, known as JAK2-IN-9, is a selective JAK2 inhibitor with an IC50 of 5 nM.Formule :C20H24N6O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :412.514-(3'-HYDROXYPHENYL)AMINO-6,7-DIMETHOXYQUINAZOLINE, HCL
CAS :Formule :C16H16ClN3O3Degré de pureté :97.0%Masse moléculaire :333.7695AG490
CAS :AG490 inhibits EGFR (0.1 μM IC50), 135x > selective than ErbB2, blocks JAK2, spares Lyn, Lck, Syk, Btk, Src.Formule :C17H14N2O3Degré de pureté :98.6% - 99.39%Couleur et forme :Yellow SolidMasse moléculaire :294.3BD750
CAS :BD750 is an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation(IC50 of 1.5 μM and 1.1 μM inFormule :C14H13N3OSDegré de pureté :99.02%Couleur et forme :SolidMasse moléculaire :271.34WHI-P180 Hydrochloride
CAS :Formule :C16H15N3O3·HClDegré de pureté :>97.0%(T)(HPLC)Couleur et forme :White to Light gray to Light yellow powder to crystalMasse moléculaire :333.77Fedratinib hydrochloride hydrate
CAS :Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.Formule :C27H40Cl2N6O4SDegré de pureté :98.96% - 99.46%Couleur et forme :SolidMasse moléculaire :615.61JAK-IN-3
CAS :JAK-IN-3 is a potent JAK inhibitor that inhibits JAK3, JAK1, TYK2, and JAK2, and can be used for the study of immune system disorders.Formule :C18H20N4O3Degré de pureté :98.04% - 98.19%Couleur et forme :SolidMasse moléculaire :340.38Ref: TM-T11704
1mg133,00€2mg188,00€5mg321,00€10mg518,00€25mg1.035,00€50mg1.644,00€100mg2.680,00€200mg3.591,00€1mL*10mM (DMSO)354,00€Momelotinib Mesylate
CAS :Momelotinib Mesylate is an ATP-competitive JAK1/JAK2 inhibitor (IC50: 11 nM/18 nM). It has 10-fold selectivity versus JAK3.Formule :C24H26N6O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :510.57Delgocitinib
CAS :Delgocitinib is a potent JAK inhibitor (IC50: 2.8-58 nM), treats inflammatory diseases, and is the first topical drug for atopic dermatitis.Formule :C16H18N6ODegré de pureté :99.90%Couleur et forme :SolidMasse moléculaire :310.35Ref: TM-T15096
1mg169,00€5mg311,00€10mg487,00€25mg929,00€50mg1.415,00€100mg2.062,00€200mg2.775,00€1mL*10mM (DMSO)349,00€CP-352664
CAS :CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.Formule :C18H18N4Couleur et forme :SolidMasse moléculaire :290.36LFM-A13
CAS :LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR,Formule :C11H8Br2N2O2Degré de pureté :99.9%Couleur et forme :SolidMasse moléculaire :360JAK1-IN-10
CAS :JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, functions as a potent and selective inhibitor of JAK1 [1].Formule :C15H17N7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :295.34Tyk2-IN-20
CAS :Tyk2-IN-20 (Example 289) is an effective inhibitor of Tyk2 with an IC50 value below 5 nM. Additionally, it inhibits JAK1, JAK2, and JAK3 with IC50 values under 100 nM. This compound is utilized for the research of inflammatory diseases.Formule :C24H25N7O2Couleur et forme :SolidMasse moléculaire :443.50Brepocitinib
CAS :Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).Formule :C18H21F2N7ODegré de pureté :99.8%Couleur et forme :SolidMasse moléculaire :389.4Ref: TM-TQ0010
1mg35,00€5mg74,00€10mg110,00€25mg226,00€50mg411,00€100mg660,00€200mg917,00€1mL*10mM (DMSO)81,00€RO8191
CAS :RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.Formule :C14H5F6N5ODegré de pureté :98.85% - ≥98%Couleur et forme :SolidMasse moléculaire :373.21MM-589 TFA
CAS :MM-589 TFA is a potent WD repeat domain 5 (WDR5)inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.Formule :C30H45F3N8O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :686.72Atractylenolide I
CAS :Atractylenolide-I reduces inflammation, improves sepsis, liver, and kidney function, and enhances EOC cell sensitivity to paclitaxel.Formule :C15H18O2Degré de pureté :97.55% - 99.83%Couleur et forme :SolidMasse moléculaire :230.3AJI-214
CAS :AJI-214 functions as a dual-target inhibitor that specifically blocks Aurora kinase A and JAK2. By directly inhibiting Aurora kinase A, AJI-214 prevents mitotic progression and cell polarity in T cells while concurrently suppressing JAK2 activation to reduce STAT3 phosphorylation. This inhibition decreases the differentiation of TH1 and TH17 cells. AJI-214 is utilized in research focused on the modulation of immune responses and the prevention of graft-versus-host disease (GVHD).Formule :C17H13ClFN5OCouleur et forme :SolidMasse moléculaire :357.77WDR5-IN-6
CAS :WDR5-IN-6 is a WDR5 inhibitor targeting the WBM locus.WDR5-IN-6 is highly synergistic with OICR-9429, a WDR5 inhibitor that targets the WIN locus.WDR5-IN-6Formule :C13H8Cl2N2O2SDegré de pureté :99.69%Couleur et forme :SoildMasse moléculaire :327.19JAK kinase-IN-1
CAS :JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32Formule :C17H19F2N7OSDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :407.44ITK inhibitor 2
CAS :ITK inhibitor 2 is a interleukin-2-inducible T-cell kinase (ITK) inhibitor , with an IC50 of 2 nM.Formule :C25H33N5O2Couleur et forme :SolidMasse moléculaire :435.56JAK-IN-31
CAS :JAK-IN-31 (Example 75), a JAK inhibitor, demonstrates IC50 values of ≤0.01 µM for JAK1, ≤0.01 µM for JAK2, 0.01-0.1 µM for JAK3, and ≤0.01 µM for Tyk2,Formule :C21H19N7O2S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :465.55G5-7
CAS :G5-7 is an oral JAK2 inhibitor targeting EGFR/STAT3 phosphorylation with potential for glioma research.Formule :C22H19F2NO3Degré de pureté :97.30%Couleur et forme :SolidMasse moléculaire :383.39Ref: TM-T8742
1mg50,00€5mg97,00€10mg145,00€25mg259,00€50mg374,00€100mg523,00€200mg710,00€1mL*10mM (DMSO)105,00€RO495
CAS :RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assaysFormule :C17H14Cl2N6ODegré de pureté :97.94%Couleur et forme :SolidMasse moléculaire :389.24Ref: TM-T22416
1mg64,00€2mg87,00€5mg117,00€10mg183,00€25mg354,00€50mg520,00€100mg702,00€200mg944,00€1mL*10mM (DMSO)140,00€Protosappanin A
CAS :Protosappanin A combats brain inflammation, suppresses rat heart transplant rejection, fights MRSA, and inhibits HIV with a 12.6 uM IC50.Formule :C15H12O5Degré de pureté :100% - 99.42%Couleur et forme :SolidMasse moléculaire :272.25Ref: TM-TJS1779
1mg87,00€5mg216,00€10mg354,00€25mg582,00€50mg825,00€100mg1.111,00€1mL*10mM (DMSO)197,00€Momelotinib
CAS :Momelotinib (LM-1149), an oral JAK1/2 inhibitor with IC50s 11/18 nM, blocks ATP binding, disrupting JAK-STAT pathway and reducing tumor growth.Formule :C23H22N6O2Degré de pureté :97.47% - 99.56%Couleur et forme :SolidMasse moléculaire :414.46Ref: TM-T1849
1mg38,00€2mg49,00€5mg81,00€10mg95,00€25mg166,00€50mg259,00€100mg406,00€200mg625,00€1mL*10mM (DMSO)88,00€JAK-IN-34
CAS :JAK-IN-34 (compound 11n) is a potent inhibitor of Janus kinases (JAKs), demonstrating IC50 values of 0.40 nM for JAK1, 0.83 nM for JAK2, 2.10 nM for JAK3,Formule :C27H26N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :450.53JAK3/BTK-IN-2
CAS :JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor.Formule :C25H32N8O2Degré de pureté :99.64%Couleur et forme :SolidMasse moléculaire :476.57GLPG0634 analog
CAS :GLPG0634 analog (GLPG0634 analogue) is a specific JAK1 inhibitor with IC50 of 10/28/810/116 nM for JAK1/2/3 and TYK2, respectively.Formule :C23H18N6O2Degré de pureté :100% - 99.22%Couleur et forme :SolidMasse moléculaire :410.43Ref: TM-T3076
1mg40,00€2mg52,00€5mg88,00€10mg144,00€25mg264,00€50mg465,00€100mg658,00€500mg1.378,00€1mL*10mM (DMSO)87,00€XL019
CAS :XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.Formule :C25H28N6O2Degré de pureté :99.19%Couleur et forme :SolidMasse moléculaire :444.53WP1066
CAS :WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3.Formule :C17H14BrN3ODegré de pureté :98.92% - 99.73%Couleur et forme :SolidMasse moléculaire :356.22SC99
CAS :SC99 inhibits JAK2-STAT3, reducing STAT3 genes, platelet activity, and has anti-myeloma, anti-thrombotic effects.Formule :C15H8Cl2FN3ODegré de pureté :99.56%Couleur et forme :SolidMasse moléculaire :336.15Ref: TM-T8719
1mg46,00€5mg93,00€10mg140,00€25mg240,00€50mg363,00€100mg452,00€200mg630,00€1mL*10mM (DMSO)99,00€SAR-20347
CAS :SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).Formule :C21H18ClFN4O4Degré de pureté :99.35% - 99.77%Couleur et forme :SolidMasse moléculaire :444.84Ref: TM-T4210
1mg35,00€5mg80,00€10mg116,00€25mg227,00€50mg354,00€100mg588,00€200mg818,00€1mL*10mM (DMSO)88,00€BMS-911543
CAS :BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. Phase 1/2.Formule :C23H28N8ODegré de pureté :97.69% - 99.98%Couleur et forme :SolidMasse moléculaire :432.52Decernotinib
CAS :Decernotinib (VRT-831509)(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.Formule :C18H19F3N6ODegré de pureté :100% - 99.45%Couleur et forme :SolidMasse moléculaire :392.38Ref: TM-T2636
1mg38,00€2mg52,00€5mg79,00€10mg110,00€25mg217,00€50mg329,00€100mg494,00€200mg705,00€1mL*10mM (DMSO)88,00€CHZ868
CAS :CHZ868 is a type II JAK inhibitor with potential antitumor activity that reverses the persistence of type I JAK inhibitors and can be used to study leukemia.Formule :C22H19F2N5O2Degré de pureté :99.38%Couleur et forme :SolidMasse moléculaire :423.42Milpecitinib
CAS :Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.Formule :C20H20N4O2SCouleur et forme :SolidMasse moléculaire :380.463Ilginatinib
CAS :Ilginatinib (NS-018) is a highly active and orally bioavailable inhibitor of JAK2.Formule :C21H20FN7Degré de pureté :98.40% - 99.01%Couleur et forme :SolidMasse moléculaire :389.43Ref: TM-T12266
1mg64,00€5mg138,00€10mg187,00€25mg273,00€50mg393,00€100mg562,00€200mg743,00€1mL*10mM (DMSO)133,00€JANEX-1
CAS :JANEX-1: cell-permeable, reversible Jak3 inhibitor (IC50: 78 μM), ATP-competitive, selective; weak on JAK1/2, Zap/Syk, SRC.Formule :C16H15N3O3Degré de pureté :98% - 99.73%Couleur et forme :SolidMasse moléculaire :297.31Ref: TM-T2045
1mg44,00€2mg55,00€5mg92,00€10mg150,00€25mg248,00€50mg444,00€100mg652,00€500mg1.378,00€1mL*10mM (DMSO)92,00€MM-589
CAS :MM-589 is a potent WD repeat domain 5 (WDR5) inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.Formule :C28H44N8O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :572.70Povorcitinib phosphate
CAS :Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.Formule :C23H25F5N7O5PDegré de pureté :97.71%Couleur et forme :SolidMasse moléculaire :605.45Ref: TM-T39113L
1mg65,00€2mg95,00€5mg145,00€10mg212,00€25mg359,00€50mg512,00€100mg695,00€200mg937,00€JAK-IN-33
JAK-IN-33 (Compound 3 (R)) is a selective inhibitor of the Janus kinase (JAK) family [1].Degré de pureté :98%Couleur et forme :Odour SolidPeficitinib
CAS :Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.Formule :C18H22N4O2Degré de pureté :98.67% - 99.4%Couleur et forme :SolidMasse moléculaire :326.39Ref: TM-T6933
2mg40,00€5mg66,00€10mg104,00€25mg182,00€50mg283,00€100mg439,00€200mg645,00€1mL*10mM (DMSO)73,00€FLLL32
CAS :FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).Formule :C28H32O6Degré de pureté :96.39% - 97.90%Couleur et forme :SolidMasse moléculaire :464.55Ref: TM-T6838
2mg46,00€5mg66,00€10mg93,00€25mg124,00€50mg197,00€100mg350,00€500mg840,00€1mL*10mM (DMSO)72,00€Cerdulatinib hydrochloride
CAS :Cerdulatinib hydrochloride is an oral tyrosine kinase inhibitor targeting JAK1/2/3, TYK2, Syk, and 19 others with IC50 < 200 nM.Formule :C20H28ClN7O3SDegré de pureté :99.23%Couleur et forme :SolidMasse moléculaire :482Ifidancitinib
CAS :Ifidancitinib (ATI-50002) is a JAK kinase 1/3 inhibitor used to study autoimmune diseases.Formule :C20H18FN5O3Degré de pureté :98.05%Couleur et forme :SolidMasse moléculaire :395.39JAK-IN-10
CAS :JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.Formule :C20H18FN5O3SDegré de pureté :98.88%Couleur et forme :SolidMasse moléculaire :427.45Ref: TM-T13571
1mg87,00€5mg177,00€10mg260,00€25mg429,00€50mg605,00€100mg815,00€500mg1.624,00€1mL*10mM (DMSO)188,00€Cerdulatinib
CAS :Cerdulatinib (PRT2070) is an novel oral dual Syk/JAK inhibitor.Formule :C20H27N7O3SDegré de pureté :98.74% - 99.49%Couleur et forme :SolidMasse moléculaire :445.54Ref: TM-T2487
1mg44,00€2mg55,00€5mg79,00€10mg106,00€25mg185,00€50mg283,00€100mg432,00€200mg605,00€500mg938,00€1mL*10mM (DMSO)86,00€Tofacitinib Citrate
CAS :Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).Formule :C22H28N6O8Degré de pureté :99.19% - 99.75%Couleur et forme :SolidMasse moléculaire :504.49TAK-901
CAS :TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among othersFormule :C28H32N4O3SDegré de pureté :97.38% - 99.1%Couleur et forme :SolidMasse moléculaire :504.64Brevilin A
CAS :Brevilin A, a sesquiterpene from Centipeda minima, hinders JAK and blocks STAT3 (IC50=10.6μM), inducing apoptosis and autophagy in cancer cells.Formule :C20H26O5Degré de pureté :100% - 99.74%Couleur et forme :SolidMasse moléculaire :346.42Ref: TM-T4672
1mg96,00€5mg215,00€10mg369,00€25mg610,00€50mg840,00€100mg1.130,00€500mg2.308,00€1mL*10mM (DMSO)235,00€Ilginatinib hydrochloride
CAS :Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.Formule :C21H21ClFN7Degré de pureté :99.55%Couleur et forme :SolidMasse moléculaire :425.89Ref: TM-T12266L2
1mg77,00€5mg165,00€10mg240,00€25mg408,00€50mg562,00€100mg800,00€200mg1.074,00€1mL*10mM (DMSO)177,00€2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
CAS :2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity and physicochemical properties.Formule :C16H13Cl2N3O2Degré de pureté :98.77%Couleur et forme :SolidMasse moléculaire :350.2JAK-IN-5 hydrochloride
CAS :JAK-IN-5 hydrochloride is a JAK inhibitor [1].Formule :C27H32ClFN6OCouleur et forme :SolidMasse moléculaire :511.03JAK3-IN-6
CAS :JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nMFormule :C19H18N4O3Degré de pureté :97.46% - 99.94%Couleur et forme :SolidMasse moléculaire :350.37Cenacitinib
CAS :Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.Formule :C19H19F2N7O3Couleur et forme :SolidMasse moléculaire :431.40JAK/HDAC-IN-2
JAK/HDAC-IN-2, a potent 2-amino-4-phenylaminopyrimidine dual-target inhibitor, effectively suppresses JAK1/2 and HDAC3/6 at nanomolar concentrations.Formule :C28H38N6O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :570.7Nimucitinib
CAS :Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.Formule :C25H26F2N6O2Degré de pureté :98.71%Couleur et forme :SoildMasse moléculaire :480.51Ref: TM-T67907
1mg96,00€2mg139,00€5mg227,00€10mg354,00€25mg653,00€50mg938,00€100mg1.454,00€500mg2.822,00€JAK2-IN-6
CAS :JAK2-IN-6: A potent JAK2-specific inhibitor (IC50=22.86μg/mL), blocks JAK2 signaling, has anticancer properties, and is inactive against JAK1/3.Formule :C14H10ClN3OS2Degré de pureté :99.38%Couleur et forme :SolidMasse moléculaire :335.83JAK3 covalent inhibitor-1
CAS :JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM andFormule :C22H17FN6O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :448.47Brepocitinib P-Tosylate
CAS :Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).Formule :C25H29F2N7O4SDegré de pureté :99.82% - 99.97%Couleur et forme :SolidMasse moléculaire :561.6Dual Cathepsin L/JAK-IN-1
CAS :DualCathepsinL/JAK-IN-1 (Compound A8) serves as a dual inhibitor of Cathepsin L (CTSL) and JAK, exhibiting IC50 values of 0.68 μM for CTSL and 337.1 nM, 5.251 nM, 27.29 nM, and 172.6 nM for JAK1/2/3 and TYK2, respectively. This compound effectively prevents the activation of MAPK, NF-κB, and JAK/STAT signaling pathways, leading to significant anti-inflammatory therapeutic effects. DualCathepsinL/JAK-IN-1 is applicable in research on acute lung injury (ALI).Formule :C19H18ClN5Couleur et forme :SolidMasse moléculaire :351.833Jaspamycin
CAS :Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα.Formule :C12H12N4O5Couleur et forme :SolidMasse moléculaire :292.25AT9283
CAS :AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).Formule :C19H23N7O2Degré de pureté :99.83% - 99.98%Couleur et forme :SolidMasse moléculaire :381.43Ref: TM-T3068
1mg47,00€2mg60,00€5mg95,00€10mg170,00€25mg299,00€50mg499,00€100mg723,00€1mL*10mM (DMSO)97,00€Pacritinib
CAS :Pacritinib (SB1518) (SB1518) is an effective and specific inhibitor of JAK2 and FLT3 (IC50: 23/22 nM, in cell-free assays).Formule :C28H32N4O3Degré de pureté :99.25% - 99.49%Couleur et forme :SolidMasse moléculaire :472.58Upadacitinib
CAS :Upadacitinib (ABT-494), a selective JAK1 inhibitor, is researched for autoimmune diseases; IC50: 43 nM.Formule :C17H19F3N6ODegré de pureté :98.96% - 99.93%Couleur et forme :SolidMasse moléculaire :380.37Ref: TM-T7503
1mg47,00€2mg62,00€5mg89,00€10mg130,00€25mg220,00€50mg306,00€100mg434,00€200mg662,00€500mg1.169,00€1mL*10mM (DMSO)48,00€Gandotinib
CAS :LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM).Formule :C23H25ClFN7ODegré de pureté :99.33% - 99.86%Couleur et forme :SolidMasse moléculaire :469.94Ref: TM-T2638
5mg51,00€10mg88,00€25mg160,00€50mg296,00€100mg469,00€500mg1.035,00€1mL*10mM (DMSO)57,00€JAK2-IN-7
CAS :JAK2-IN-7 selectively inhibits JAK2 (IC50: 3 nM), shows 14-fold selectivity over JAK1/3, FLT3, induces G0/G1 arrest, apoptosis, and has antitumor effects.Formule :C26H33N7ODegré de pureté :98.71%Couleur et forme :SolidMasse moléculaire :459.59Ref: TM-T35900
1mg145,00€5mg354,00€10mg630,00€25mg1.301,00€50mg1.738,00€100mg2.357,00€1mL*10mM (DMSO)358,00€AZ-3
CAS :AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM).Formule :C20H28FN7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :385.48JAK-IN-28
CAS :JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor potentially applicable in the research of cancer and inflammatory diseases [1].Formule :C20H18ClN7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :407.86JBJ-04-125-02
CAS :JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.Formule :C29H26FN5O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :543.61JAK3-IN-7
CAS :JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction afterFormule :C17H20N6ODegré de pureté :98.81%Couleur et forme :SolidMasse moléculaire :324.38Tyrphostin AG 490
CAS :Formule :C17H14N2O3Degré de pureté :>98.0%(T)(HPLC)Couleur et forme :White to Light yellow powder to crystalMasse moléculaire :294.31DTP3
CAS :DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.Formule :C26H35N7O5Couleur et forme :SolidMasse moléculaire :525.6Pumecitinib
CAS :Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.Formule :C17H20N8O2SDegré de pureté :99.89%Couleur et forme :SoildMasse moléculaire :400.46RGB-286638 free base
CAS :RGB-286638 free base inhibits CDKs (1-5 nM), weaker on CDK7/6.Formule :C29H35N7O4Degré de pureté :97.29% - 99.91%Couleur et forme :SolidMasse moléculaire :545.63Fosifidancitinib
CAS :Fosifidancitinib is a potent inhibitor of JAK 1 and JAK 3.Formule :C21H21FN5O7PDegré de pureté :99.55%Couleur et forme :SolidMasse moléculaire :505.39Ref: TM-T38624
1mg87,00€2mg124,00€5mg187,00€10mg284,00€25mg452,00€50mg645,00€100mg867,00€200mg1.159,00€STAT3-IN-18
CAS :STAT3-IN-18 (compound SPP), a platinum (IV) complex featuring an axial ligand from sandalwood, suppresses the JAK2-STAT3 pathway in breast cancer (BC) cells andFormule :C18H24Cl2N2O6PtDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :630.38
